The secret for success in molecular imaging relies on the capability of new compounds to respond to three "simple" questions, which that represent as many key steps prior to any consensus indication. First, is the tracer sensible sensitive and specific enough as molecular probe? Second, does its use respond to a real clinical need? Third, did it undergone proper scientific validation before getting into clinics? If any of these passages fails, than it is very unlikely for the tracer to cross the line and get the approval. This article is protected by copyright. All rights reserved.
BJU international. 2019 Feb 20 [Epub ahead of print]
Egesta Lopci, Arnoldo Piccardo, Massimo Lazzeri
Nuclear Medicine Unit, Humanitas Clinical and Research Hospital - IRCCS, Rozzano, Italy., Department of Nuclear Medicine, Galliera Hospital, Genoa, Italy., Department of Urology, Humanitas Clinical and Research Hospital - IRCCS, Rozzano, Italy.